Authors
Emil Brink Wriedt, Mads Joon Jorsal, Sam Kafai Yahyavi, Li Juel Mortensen, Ebbe Eldrup, Anders Juul, Rune Holt, Martin Blomberg Jensen
Published in
Endocrine. Volume 91. Issue 1. Jun 25, 2026. Epub Jun 25, 2026.
Abstract
Infertile men have an increased prevalence of metabolic syndrome. Denosumab has been shown to lower HbA1c in older patients with impaired glucose tolerance. We hypothesized that denosumab will lower HbA1c in a cohort of young infertile men.
This was a secondary analysis of a single-center, placebo-controlled randomized clinical trial comprising infertile men with no serious co-morbidities. Men were randomized 1:1 to receive a single s.c. injection of 60 mg denosumab or placebo. Prespecified secondary outcome variables included HbA1c, fasting glucose, fasting insulin, C-peptide, while the primary end point semen quality has previously been reported.
We randomized 100 infertile men and 92 were included in the final analysis. There were no differences between denosumab and placebo groups at day 80 or 160 for HbA1c, LDL, HDL or total cholesterol. For fasting patients (n = 44) there were no differences in plasma glucose, plasma insulin, C-peptide, or HOMA-IR. At day 160 alanine aminotransferase was higher in the denosumab group compared to placebo 8.3 U/L (95% CI 3.3 to 13.3). In a subgroup with high baseline serum cortisol, denosumab reduced HbA1c by 2.5 mmol/mol (95% CI -5.0 to -0.1) compared to placebo.
A single dose of denosumab had no effect on glucose- or lipid homeostasis but induced a small increase in serum ALT in young infertile men with no serious co-morbidities.
NCT03030196.
PMID:
42347899
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0